| abstract |
The present invention shows compounds having the structure: wherein X is O, S, CH2 or NR5; Y is O or S; R1 is H, C1C15 substituted or unsubstituted alkyl C1-C8 alkylaryl, -C (O) OR4, -C (O) NR4R5, -CR6R6 ?? OR4, -CR6R6 ?? OC (O) R4, -CR6R6 ?? OC (O) NHR7, -C (O) NR10R11, -C (O) NR8R9, -N (R5) C (O) NHR5, OR CH2R4; R2 is a C1-C30 substituted or unsubstituted straight chain alkyl, or C3C30 alkyl, aryl, alkylaryl, arylalkyl, heteroarylalkyl or branched cycloalkyl; R3 is H or C1-C6 alkyl or C3-C10 substituted or unsubstituted cycloalkyl; R4 is H or a C6-C30 alkyl, aryl, -CH2-aryl, aryl-C1-C15alkyl, heteroaryl-C1-C15alkyl or C3-C10 straight or branched, substituted or unsubstituted cycloalkyl; R5 is H or a C6-C30 alkyl, C6-C30 aryl alkyl, heteroarylalkyl or straight or branched chain, substituted or unsubstituted cycloalkyl; R6 and R6` are each independently H, C1-C6 alkyl, dialkyl or C3-C10 substituted cycloalkyl or are substituted or together form a 3-7 membered ring system; R7 is H or C1-C12 alkyl or C3-C10 substituted or unsubstituted cycloalkyl; R8 and R9 are each independently H, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 substituted or unsubstituted alkylaryl, or NR8R9 together form a substituted peperazine or piperidine ring or a dihydro-1H-isoquinoline ring system, or a specific enantiomer thereof. Or a specific tautomer, or a pharmaceutically acceptable salt thereof and a method of treating diabetes or obesity by administering a therapeutically effective amount of the compounds of the invention. |